Benzinga | Oct 29, 2020 09:16AM EDT

Piper Sandler Maintains Overweight on ChemoCentryx, Raises Price Target to $71

Piper Sandler maintains ChemoCentryx (NASDAQ:CCXI) with a Overweight and raises the price target from $67 to $71.